Due to its broad spectrum of action, Sorafenib was combined with standard chemotherapy in the randomized SORAML trial, where 267 patients ≤60 years with newly diagnosed AML, irrespective of FLT3 status (only 17% had FLT3-ITDmut), received 3 + 7 induction and high-dose Cytarabine consolidation with or without Sorafenib [26]. Here, FLT3 is linked to acute myeloid leukemia.